Therapeutic Approaches Targeting Pathological Tau Aggregates

Author(s): Julia Gerson, Rakez Kayed

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 26 , 2016

Become EABM
Become Reviewer
Call for Editor


Neurodegenerative diseases characterized by the accumulation of tau aggregates are increasing in prevalence to epidemic-like levels and there is currently no effective treatment. For many years, the focus of tau-based research was on the fibrillar, neurofibrillary tangles. However, the compilation of evidence obtained from numerous laboratories in the past few years suggests that soluble intermediate aggregates—tau oligomers—are actually the most toxic protein species in disease. Thus, therapeutic agents that target oligomeric tau specifically may be the most effective routes for treatment. A great deal of progress has been made in the pre-clinical evaluation of a number of different anti-tau therapeutics. Upstream modulators of tau modifications have been evaluated and may provide some benefits, but likely will not be capable of eliminating toxic tau entirely. Protein chaperones capable of modulating the structure of tau and targeting it for degradation are another field of study, however, the broad effects of chaperones make side effects a concern. Thus, more specific agents capable of eliminating the most toxic species in disease are promising. Small molecules designed to inhibit aggregation, as well as immunotherapy with antibodies specific for toxic tau aggregates present the most advancement as potential treatments. The concerted effort across a number of groups to investigate potential mechanisms to inhibit tau toxicity represents great progress in the field and provides hope that effective treatments will be discovered.

Keywords: Tau aggregation, tau oligomers, pathological tau, small molecules, immunotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 18 May, 2016
Page: [4028 - 4039]
Pages: 12
DOI: 10.2174/1381612822666160518142226
Price: $65

Article Metrics

PDF: 67